GYRE
Price
$8.04
Change
+$0.07 (+0.88%)
Updated
Jun 6, 10:32 AM (EDT)
Capitalization
717.17M
74 days until earnings call
OCGN
Price
$0.99
Change
+$0.04 (+4.21%)
Updated
Jun 6, 10:59 AM (EDT)
Capitalization
278.28M
56 days until earnings call
Interact to see
Advertisement

GYRE vs OCGN

Header iconGYRE vs OCGN Comparison
Open Charts GYRE vs OCGNBanner chart's image
Gyre Therapeutics
Price$8.04
Change+$0.07 (+0.88%)
Volume$1.43K
Capitalization717.17M
Ocugen
Price$0.99
Change+$0.04 (+4.21%)
Volume$3.35K
Capitalization278.28M
GYRE vs OCGN Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. OCGN commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a StrongBuy and OCGN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (GYRE: $7.94 vs. OCGN: $0.95)
Brand notoriety: GYRE and OCGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 111% vs. OCGN: 260%
Market capitalization -- GYRE: $717.17M vs. OCGN: $278.28M
GYRE [@Biotechnology] is valued at $717.17M. OCGN’s [@Biotechnology] market capitalization is $278.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileOCGN’s FA Score has 0 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • OCGN’s FA Score: 0 green, 5 red.
According to our system of comparison, both GYRE and OCGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 5 TA indicator(s) are bullish while OCGN’s TA Score has 4 bullish TA indicator(s).

  • GYRE’s TA Score: 5 bullish, 5 bearish.
  • OCGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both GYRE and OCGN are a good buy in the short-term.

Price Growth

GYRE (@Biotechnology) experienced а -16.07% price change this week, while OCGN (@Biotechnology) price change was +14.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

OCGN is expected to report earnings on Aug 01, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($717M) has a higher market cap than OCGN($278M). OCGN YTD gains are higher at: 18.373 vs. GYRE (-34.380). GYRE has higher annual earnings (EBITDA): 11.8M vs. OCGN (-54.34M). OCGN has more cash in the bank: 37.8M vs. GYRE (25.1M). GYRE has less debt than OCGN: GYRE (1.8M) vs OCGN (31.8M). GYRE has higher revenues than OCGN: GYRE (105M) vs OCGN (4.52M).
GYREOCGNGYRE / OCGN
Capitalization717M278M258%
EBITDA11.8M-54.34M-22%
Gain YTD-34.38018.373-187%
P/E Ratio397.00N/A-
Revenue105M4.52M2,322%
Total Cash25.1M37.8M66%
Total Debt1.8M31.8M6%
FUNDAMENTALS RATINGS
GYRE vs OCGN: Fundamental Ratings
GYRE
OCGN
OUTLOOK RATING
1..100
6729
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
9394
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
8244
P/E GROWTH RATING
1..100
7100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCGN's Valuation (76) in the null industry is in the same range as GYRE (94). This means that OCGN’s stock grew similarly to GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (93) in the null industry is in the same range as OCGN (94). This means that GYRE’s stock grew similarly to OCGN’s over the last 12 months.

GYRE's SMR Rating (96) in the null industry is in the same range as OCGN (98). This means that GYRE’s stock grew similarly to OCGN’s over the last 12 months.

OCGN's Price Growth Rating (44) in the null industry is somewhat better than the same rating for GYRE (82). This means that OCGN’s stock grew somewhat faster than GYRE’s over the last 12 months.

GYRE's P/E Growth Rating (7) in the null industry is significantly better than the same rating for OCGN (100). This means that GYRE’s stock grew significantly faster than OCGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYREOCGN
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFIVX24.600.02
+0.08%
DFA International Value I
PIIRX15.62N/A
N/A
Putnam International Value R
MLPEX7.48N/A
N/A
Invesco SteelPath MLP Select 40 C
IEQAX16.07N/A
N/A
ICON Equity Income Investor
CRVRX8.14N/A
N/A
NYLI CBRE Real Estate Fund Investor Cl

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-7.46%
SPRC - GYRE
38%
Loosely correlated
+4.95%
PYXS - GYRE
37%
Loosely correlated
-3.52%
AURA - GYRE
37%
Loosely correlated
-0.57%
BEAM - GYRE
36%
Loosely correlated
-0.87%
CRBU - GYRE
36%
Loosely correlated
-3.54%
More

OCGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCGN has been loosely correlated with RAIN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if OCGN jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCGN
1D Price
Change %
OCGN100%
+7.41%
RAIN - OCGN
53%
Loosely correlated
+6.24%
ARRY - OCGN
47%
Loosely correlated
+6.16%
IPSC - OCGN
47%
Loosely correlated
-0.71%
AXON - OCGN
46%
Loosely correlated
+1.08%
ERAS - OCGN
44%
Loosely correlated
+2.61%
More